Intuitive Surgical (ISRG) Earnings Date & Reports

Key Takeaways

• Revenue rose 21.7% year over year to $3.05 billion, topping FactSet consensus of roughly $2.91 billion.
• Adjusted earnings per share (EPS) came in at $3.00, well above analyst estimates of about $2.64 to $2.65.
• GAAP (Generally Accepted Accounting Principles) net income fell to $522.8 million, or $1.49 per share, down from $704.4 million, or $1.95 per share, a year earlier, hurt by a litigation charge.
• Worldwide procedures grew about 15%, with da Vinci procedures up 14% and Ion procedures up 31%.
• Full-year 2026 da Vinci procedure growth guidance was narrowed to a 14% to 15% range.
• Shares slid roughly 10% in after-hours trading despite the earnings beat.

Earnings Context and Why It Matters

Intuitive Surgical is the global leader in robotic-assisted surgery, and its quarterly results are closely watched as a barometer of hospital capital spending and demand for minimally invasive procedures. The company has a long track record of exceeding Wall Street expectations, driven by rising procedure volumes and a growing installed base of da Vinci systems. This third-quarter report mattered because it tested whether strong procedure growth could persist, while also revealing the financial impact of a significant litigation charge. Investors were watching both the top-line momentum and the durability of the company's guidance heading into the end of the fiscal year.

Reported Results

Intuitive Surgical reported third-quarter 2026 revenue of $3.05 billion, up 21.7% from $2.51 billion in the prior-year period and above the FactSet consensus of approximately $2.91 billion. Adjusted EPS was $3.00, comfortably exceeding analyst expectations of roughly $2.64 to $2.65 per share.

On a GAAP basis, net income declined to $522.8 million, or $1.49 per diluted share, compared with $704.4 million, or $1.95 per diluted share, a year earlier. The drop reflected a pretax litigation charge that reduced earnings by about 99 cents per share after tax.

Operationally, worldwide procedures grew approximately 15%, driven by 14% growth in da Vinci procedures and 31% growth in Ion procedures. The company placed 546 da Vinci surgical systems, up from 427 a year earlier, including 315 da Vinci 5 systems versus 240 in the prior-year quarter. Instruments and accessories revenue rose 18% to $1.80 billion, while systems revenue climbed to $769 million from $590 million a year ago. Intuitive ended the period with about $6.80 billion in cash, cash equivalents, and investments.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking robotic-surgery and medical-device names, tools like this can surface actionable watchlists quickly. Explore the AI Screener to see how AI-driven filtering can support your research process.

Market Reaction and Investor Sentiment

Despite beating top- and bottom-line estimates, Intuitive Surgical shares fell sharply in after-hours trading, dropping roughly 10% to around $391 per share. The decline was largely attributed to the company's full-year procedure guidance, which was narrowed to a 14% to 15% range, down from the prior outlook of 13.5% to 15.5%. While the midpoint of the new range remained intact, the reduced upper bound appeared to disappoint investors who had hoped for stronger momentum. The litigation charge also weighed on GAAP profitability, even though adjusted results remained robust. Overall, the market's reaction reflected high expectations built into the stock rather than any fundamental deterioration in the business.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should focus on procedure volume trends, which remain the primary driver of Intuitive Surgical's recurring revenue. The company's narrowed guidance of 14% to 15% growth in worldwide da Vinci procedures for 2026 will be a key benchmark to track in the fourth quarter.

System placements and the adoption of the da Vinci 5 platform are also worth watching. Strong da Vinci 5 placements signal customer appetite for upgrades and capacity expansion, but the timing of capital purchases can be uneven. The rapid growth of the Ion platform, used for minimally invasive lung biopsies, represents another important long-term catalyst as the company expands reimbursement and geographic access.

Margin trends and the effects of pricing actions on high-volume benign procedures may influence profitability in future quarters. Additionally, international expansion, particularly in Europe and Asia, remains a meaningful opportunity even as the operating environment in China stays challenging. Investors will likely monitor whether procedure growth can reaccelerate and whether the litigation matter has any further financial implications.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations